Is tofacitinib/Shangjie an immunosuppressant or a biological agent?

The classification of Tofacitinib often causes confusion among patients and some members of the public because it is widely used in immune-related diseases such as rheumatoid arthritis, psoriatic arthritis, ulcerative colitis (UC), and ankylosing spondylitis, and its mechanism of action is different from traditional biological agents. In fact, tofacitinib should be classified as a small molecule targeted immunosuppressant rather than a biologic.

Immunosuppressants have a wide range, including classic drugs such as glucocorticoids, methotrexate, and cyclosporine. These drugs often alleviate the disease by suppressing the immune response on a large scale, but they have many side effects. Tofacitinib belongs to a new class of selective JAK inhibitors. It inhibits the activity of multiple inflammatory cytokines by blocking the JAK-STAT signaling pathway, thereby achieving the purpose of controlling immune overreaction. This targeting effect makes it significantly different from traditional non-specific immunosuppressants.

In contrast, biological agents are usually protein or antibody drugs prepared through genetic engineering technology. They are larger in size and have complex molecules, and must be injected or infused into the body. Most of them target specific inflammatory factors, such asTNF-α inhibitors or IL-6 receptor antagonists. Tofacitinib is a chemically synthesized small molecule drug that can be absorbed orally. It has predictable pharmacokinetics and a relatively mature production process, so it cannot be classified as a biological agent.

It is worth emphasizing that although tofacitinib is called an immunosuppressant, its mode of action is more precise. It does not generally weaken immunity, but achieves immune regulation through targeted inhibition of specific signaling pathways. This means that while patients obtain curative effects, they may face a more reasonable risk-benefit ratio compared to traditional drugs. Therefore, tofacitinib/Shangjie is a small molecule targeted immunosuppressant, not a biological agent.

Reference materials:https://www.xeljanz.com/